Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Capecitabine in Hepatocellular Carcinoma
NCT01032850Phase 2Terminated
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Sep 2009
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib, capecitabine in hepatocellular carcinoma (HCC), sponsored by New Mexico Cancer Research Alliance. Started Sep 2009; status: terminated.
02
Drugs
sorafenibcapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01032850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032850.